Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a ...
pharmaphorum5d
WCLC: Amgen eyes first-line use for KRAS drug Lumakras
Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...
pharmaphorum3y
ESMO21: First combo data with Amgen's Lumakras hit the mark in CRC
Amgen is testing a range of Lumakras-based combinations in KRAS-positive tumours, and yesterday also entered into an alliance to pair its drug with Boehringer Ingelheim's BI 1701963, a SOS1::pan ...